In summary, despite heterogeneous response to venetoclax or CDK9 inhibitors as single agents, MCL cell lines and primary samples from untreated and relapsed aggressive cases were sensitive to the concomitant inhibition of BCL‐2 and CDK9. Here, BCL2 is linked to mantle cell lymphoma.